Christopher Pocock

6.1k citations

54 papers · 2.3k · 1 hit paper · h-index 24

Impact in

Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
Hematology top 1%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research

Papers in

Genetics 26
- Chronic Lymphocytic Leukemia Research 23
Hematology 23
- Chronic Myeloid Leukemia Treatments 16
- Acute Myeloid Leukemia Research 7
- Hematopoietic Stem Cell Transplantation 6

Co-authors: David C. Linch (12 shared papers)Jane Apperley (12 shared papers)Kirit M. Ardeshna (11 shared papers)ANDREW S. JACK (9 shared papers)David Cunningham (11 shared papers)John Maelor Davies (8 shared papers)Wendi Qian (6 shared papers)John M. Goldman (10 shared papers)
Journals: Blood (22 papers)British Journal of Haematology (11 papers)The Lancet Haematology (2 papers)Hematological Oncology (2 papers)Journal of Clinical Oncology (2 papers)
Partner nations: United Kingdom Australia Switzerland

In The Last Decade

Christopher Pocock

53 papers receiving 2.2k citations

Christopher Pocock's Hit Papers

align trajectories log scale

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles 2013 · 403 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2013 The Lancet

Peers

Countries citing papers authored by Christopher Pocock

Since Specialization

Citations

This map shows the geographic impact of Christopher Pocock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Pocock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Pocock more than expected).

Fields of papers citing papers by Christopher Pocock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Pocock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Pocock. The network helps show where Christopher Pocock may publish in the future.

Co-authors

The 25 scholars most cited alongside Christopher Pocock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher Pocock Line = papers co-authored together Christopher Pocock links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles The Lancet ·David Cunningham, Eliza Anne Hawkes, ANDREW S. JACK, Wendi Qian, Paul J. Smith, Paul R. Mouncey, Christopher Pocock, Kirit M. Ardeshna, John A. Radford, Andrew McMillan, John Maelor Davies, Deborah Turner, Anton R. Kruger, Peter Johnson, Joanna Gambell, David C. Linch Hit paper breakdown →	2013	403
2	Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial The Lancet Oncology ·Kirit M. Ardeshna, Wendi Qian, Paul Smith, Nivette Braganca, Lisa Lowry, Pip Patrick, June Warden, Lindsey Stevens, Christopher Pocock, Fiona M. Miall, David Cunningham, John Maelor Davies, ANDREW S. JACK, Richard J. Stephens, Jan Andrzej Walewski, Burhan Ferhanoğlu, Ken Bradstock, David C. Linch	2014	279
3	De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial The Lancet Haematology ·(unknown), Fotios Polydoros, Jane Apperley, Dragana Milojković, Katherine A. Rothwell, Christopher Pocock, Jenny Byrne, Hugues de Lavallade, Wendy Osborne, Lisa J. Robinson, Stephen G. O’Brien, Lucy Read, Letizia Foroni, Mhairi Copland	2019	130
4	Early detection of BCR-ABL transcripts by quantitative reverse transcriptase–polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia Blood ·Eduardo Olavarría, Edward Kanfer, Richard Szydlo, Jaspal Kaeda, Katayoun Rezvani, Kate Cwynarski, Christopher Pocock, Francesco Dazzi, Charles Craddock, Jane Apperley, Nicholas C.P. Cross, John M. Goldman	2001	129
5	Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib Blood ·David Marín, Corinne A. Hedgley, Richard E. Clark, Jane Apperley, Letizia Foroni, Dragana Milojković, Christopher Pocock, John M. Goldman, Stephen J. O’Brien	2012	112
6	Richter's transformation of chronic lymphocytic leukemia Leukemia Research ·Patrick D. Thornton, Carlos Tilves Bellas, Almudena Santón, Gunjan L. Shah, Christopher Pocock, Andrew Charles Wotherspoon, Estella Matutes, Daniel Catovsky	2005	108
7	Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). PubMed ·Sarah Kulkarni, C Heath, Sally E. Parker, Andrew Chase, Syma Iqbal, Christopher Pocock, Jaspal Kaeda, Kate Cwynarski, John M. Goldman, Nicholas C.P. Cross	2000	102
8	Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study Journal of Clinical Oncology ·Peter Hillmen, John G. Gribben, George Follows, Donald William Milligan, Hazem A. Sayala, Paul Moreton, David Graham Oscier, Claire E. Dearden, Daniel B. Kennedy, Andrew R. Pettitt, Amit Chunilal Nathwani, Abraham Mullasseril Varghese, Dena R. Cohen, Andy C. Rawstron, Stephan H. K. Oertel, Christopher Pocock	2014	96
9	De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial The Lancet Haematology ·(unknown), Fotios Polydoros, Jane Apperley, Dragana Milojković, Christopher Pocock, Graeme Smith, Jenny Byrne, Hugues de Lavallade, Stephen G. O’Brien, Tony Coffey, Letizia Foroni, Mhairi Copland	2017	94
10	De Novo Treatment of Diffuse Large B-Cell Lymphoma With Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in Patients With Cardiac Comorbidity: A United Kingdom National Cancer Research Institute Trial Journal of Clinical Oncology ·Paul A. Fields, William M. Townsend, Andrew R Webb, Nicholas Counsell, Christopher Pocock, Paul Smith, ANDREW S. JACK, Nadjet El-Mehidi, Peter Johnson, John A. Radford, David C. Linch, David Cunnningham	2013	85
11	An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis Blood ·Kirit M. Ardeshna, Wendi Qian, Paul Smith, June Warden, Lindsay M. Stevens, Christopher Pocock, Fiona M. Miall, David Cunningham, John Maelor Davies, Jan Andrzej Walewski, A. Burhan Ferhanoglu, Ken F. Bradstock, David C. Linch	2010	75
12	Novel translocations that disrupt the platelet‐derived growth factor receptor β (PDGFRB) gene in BCR–ABL‐negative chronic myeloproliferative disorders British Journal of Haematology ·E. Joanna Baxter, Shashikant Kulkarni, J.L. Vizmanos, Rina J. Jaju, G Martinelli, Nicoletta Testoni, George S. Hughes, Zoryana Salamanchuk, Marı́a José Calasanz, Idoya Lahortiga, Christopher Pocock, Raymond Dang, Carrie Fidler, James S. Wainscoat, Jacqueline Boultwood, Nicholas C.P. Cross	2003	74
13	Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial Annals of Oncology ·Mary Gleeson, Nicholas Counsell, David Cunningham, Nicholas P. Chadwick, Anthony Lawrie, Eliza Anne Hawkes, Andrew McMillan, Kirit M. Ardeshna, ANDREW S. JACK, Peter Smith, Paul R. Mouncey, Christopher Pocock, John A. Radford, J. M. Davies, Deborah Turner, Anton R. Kruger, Peter Johnson, Joanna Gambell, David C. Linch	2017	61
14	Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission Blood ·Charles Craddock, Richard Szydlo, John P. Klein, Francesco Dazzi, Eduardo Olavarría, Frits van Rhee, Christopher Pocock, Kate Cwynarski, Jane Apperley, John M. Goldman	2000	56
15	Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study Haematologica ·Andrew M. Evens, Joseph M. Connors, Anas Younes, S. M. Ansell, Won Seog Kim, John A. Radford, Tatyana A. Feldman, Joseph M. Tuscano, Kerry J. J. Savage, Yasuhiro Oki, Andrew Grigg, Christopher Pocock, Monika Długosz‐Danecka, Keenan Fenton, Andres Forero‐Torres, Rachael Liu, Hina A. Jolin, Ashish Gautam, Andrea Gallamini	2021	42
16	Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐ CHOP ) in the management of primary mediastinal B‐cell lymphoma: a subgroup analysis of the UK NCRI R‐ CHOP 14 versus 21 trial British Journal of Haematology ·Mary Gleeson, Eliza Anne Hawkes, David Cunningham, Nick Chadwick, Nicholas Counsell, Anthony Lawrie, ANDREW S. JACK, Paul Smith, Paul R. Mouncey, Christopher Pocock, Kirit M. Ardeshna, John A. Radford, Andrew McMillan, John Maelor Davies, Deborah Turner, Anton R. Kruger, Peter Johnson, Joanna Gambell, David C. Linch	2016	35
17	A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia British Journal of Haematology ·Peter Hillmen, Dena R. Cohen, Kim Cocks, Andrew R. Pettitt, Hazem A. Sayala, Andy C. Rawstron, Daniel B. Kennedy, Chris Fegan, Don W. Milligan, John A. Radford, Jane Mercieca, Claire E. Dearden, Raphael Ezekwisili, Alexandra F. Smith, Julia M. Brown, Gillian Booth, Abraham Mullasseril Varghese, Christopher Pocock, (unknown)	2011	33
18	A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia Leukemia ·M W Drummond, Christopher Pocock, Marjorie Boissinot, Juliet Mills, Julia M. Brown, Pierre Cauchy, Nicholas C.P. Cross, Suzanne Hartley, Jonathan Kell, Alexander J. Szubert, Peter N. Cockerill, David Bowen	2014	32
19	Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions Bone Marrow Transplantation ·Kate Cwynarski, Rebecca Goulding, Christopher Pocock, Francesco Dazzi, Charles Craddock, Jaspal Kaeda, Eduardo Olavarría, Ed Kanfer, Jane Apperley, Mark Lawler, JM Goldman	2001	31
20	Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study Blood ·Peter Hillmen, John G. Gribben, George Follows, Donald William Milligan, Hazem A. Sayala, Paul Moreton, David Graham Oscier, Claire E. Dearden, Daniel B. Kennedy, Andrew R. Pettitt, Amit Chunilal Nathwani, Dena R. Cohen, Andy C. Rawstron, Christopher Pocock	2010	28

About Christopher Pocock

Christopher Pocock is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Oncology and Rheumatology, having authored 54 papers that have together received 2.3k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (23 papers), Lymphoma Diagnosis and Treatment (22 papers), Chronic Myeloid Leukemia Treatments (16 papers), Eosinophilic Disorders and Syndromes (7 papers), Acute Myeloid Leukemia Research (7 papers), Immunodeficiency and Autoimmune Disorders (6 papers), CNS Lymphoma Diagnosis and Treatment (6 papers) and Hematopoietic Stem Cell Transplantation (6 papers). The work is most often cited by research in Genetics (1.0k citations), Hematology (826 citations), Pathology and Forensic Medicine (1.2k citations), Oncology (704 citations) and Rheumatology (354 citations). Christopher Pocock has collaborated with scholars based in United Kingdom, Australia and Switzerland. Frequent co-authors include David C. Linch, Jane Apperley, Kirit M. Ardeshna, ANDREW S. JACK, David Cunningham, John Maelor Davies, Wendi Qian, John M. Goldman, John A. Radford and Peter Johnson. Their work appears in journals such as Blood, British Journal of Haematology, The Lancet Haematology, Hematological Oncology and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Christopher Pocock

Impact in

Papers in i

In The Last Decade

Christopher Pocock

Christopher Pocock's Hit Papers

Peers

Countries citing papers authored by Christopher Pocock

Fields of papers citing papers by Christopher Pocock

All Works

About Christopher Pocock

Explore authors with similar magnitude of impact

Papers in